Aehr Test Systems Surges 28% on Record Bookings
NEW YORK, July 21 —
Aehr Test Systems delivered fiscal 2026 fourth-quarter results with record quarterly bookings and a $100 million effective backlog, per a July 14 SEC 8-K filing. Investors responded with a 28% single-session gain. Two days later, a company director sold $1.64 million in open-market shares.
- Record quarterly bookings and $100 million effective backlog in fiscal Q4 2026
- Forward P/E of 71.5x on $50 million in trailing revenue; free cash flow negative $1 million
- Director Geoffrey Gates Scott sold 20,000 shares open-market at $82.13 on July 16, generating $1.64 million in proceeds
The Backlog Premium
A $100 million effective backlog is a striking number for a company generating $50 million in trailing-twelve-month revenue. It implies roughly two years of committed demand sitting in the pipeline, and in semiconductor test equipment, where orders are lumpy and customer visibility is scarce, that kind of coverage commands a premium. Revenue grew 33.7% year over year. The earnings beat itself was barely legible — $0.01 versus a consensus of $0.00 — but that was never the story. The market priced the pipeline.
Priced for Perfection
The 28% surge pushed Aehr to a market capitalization near $3.21 billion, a forward P/E of 71.5x, and a current price of $98.91 against an analyst consensus target of $115. At that multiple, on $50 million in trailing revenue with a gross margin of 38.5%, there is almost no tolerance for a miss. Respectable margins for a capital equipment maker do not typically anchor a premium-software-style multiple. Free cash flow is negative $1 million on a trailing basis. Everything depends on the backlog converting to revenue at the rate the valuation implies, and converting cleanly, with no timing slippage.
Two Days Later
Director Geoffrey Gates Scott sold 20,000 shares in an open-market transaction on July 16 at $82.13 per share, generating proceeds of $1.64 million. The transaction landed two days after the earnings 8-K filing, with the fiscal Q4 results fully public. Open-market sales require active intent. Scott chose to reduce his position at a price below where the stock now trades at $98.91, capturing a portion of the post-earnings move while leaving the rest behind. On the same date, he also gifted 10,000 additional shares.
CEO Gayn Erickson disposed of a combined 7,851 shares in tax-withholding transactions on July 13 and 14, at prices of $72.60 and $72.01 respectively, totaling approximately $567,949. Tax-withholding disposals are mechanically linked to equity vest dates rather than discretionary bearish conviction. Multiple executives across the leadership team, including the CFO, CTO, and EVP of R&D, received equity grants on July 1, consistent with a routine annual compensation cycle. The grant activity dilutes any sweeping negative read on insider behavior broadly.
Scott's open-market sale sits in a different category. A director who sells $1.64 million two days post-earnings, at a price the stock subsequently eclipses, is not making an administrative move.
What to Watch
The next quarterly report is the primary checkpoint. If the $100 million backlog converts at a rate that materially lifts revenue and turns free cash flow positive, the 71.5x forward multiple starts to look earned. If conversion stalls or bookings growth softens, the repricing at this valuation level will be disproportionate.
The neutral read: the backlog and 33.7% revenue growth are real, and neither is invalidated by a single director sale. But a $1.64 million open-market transaction two days after delivering what looked like a strong print, at a price since left behind, is the kind of detail worth filing away before the next earnings call. Bulls have the story; the execution now has to match it.
Run the free Aehr Test Systems, Inc. deep-dive →
Basis Report does not hold positions in securities discussed. This is not investment advice.
Frequently Asked Questions
What did Aehr Test report in fiscal Q4 2026?
Aehr Test Systems reported record quarterly bookings and a $100 million effective backlog in its fiscal 2026 fourth-quarter results, per a July 14 SEC 8-K filing. The company posted EPS of $0.01, beating the consensus estimate of $0.00.
Why did Aehr Test Systems stock surge 28%?
Shares surged 28% following the fiscal Q4 earnings release, driven by record quarterly bookings and a $100 million effective backlog rather than the thin EPS beat. Investors interpreted the backlog as strong forward demand visibility in a sector where order timing is typically unpredictable.
Is Aehr Test Systems stock overvalued?
At a forward P/E of 71.5x on $50 million in trailing revenue and negative free cash flow, Aehr leaves almost no margin for execution error. The analyst consensus price target stands at $115, with the stock currently trading at $98.91.
Are Aehr Test Systems insiders selling?
Director Geoffrey Gates Scott sold 20,000 shares in an open-market transaction two days after the earnings filing, generating proceeds of $1.64 million. CEO Gayn Erickson disposed of 7,851 shares via tax-withholding mechanisms around the same period, a routine process tied to equity vesting rather than a discretionary sale.
What is Aehr Test Systems backlog?
Aehr Test Systems reported a $100 million effective backlog in fiscal Q4 2026, roughly equivalent to two years of current trailing revenue. Converting that backlog into recognized revenue at the rate the valuation implies is the central execution test over the coming quarters.